Home Based Daratumumab Administration for Patients With Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This clinical trial tests the treatment effect of home based daratumumab administration in
treating patients with multiple myeloma. Darzalex Faspro is a combination of two drugs
(daratumumab and hyaluronidase) used to treat adults with multiple myeloma. Daratumumab is in
a class of medications called monoclonal antibodies. It works by helping the body to slow or
stop the growth of cancer cells. Hyaluronidase-fihj is an endoglycosidase. It helps to keep
daratumumab in the body longer so that the medication will have a greater effect. Standard
medical care requires Darzalex-Faspro treatment be administered during visits to the cancer
center. Receiving medication in the home setting, may decrease cost and burden of care in
patients with multiple myeloma.